1-201359618-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_001276345.2(TNNT2):c.851+5G>A variant causes a splice donor 5th base, intron change. The variant allele was found at a frequency of 0.000000691 in 1,447,102 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001276345.2 splice_donor_5th_base, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TNNT2 | NM_001276345.2 | c.851+5G>A | splice_donor_5th_base_variant, intron_variant | ENST00000656932.1 | NP_001263274.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TNNT2 | ENST00000656932.1 | c.851+5G>A | splice_donor_5th_base_variant, intron_variant | NM_001276345.2 | ENSP00000499593 | A2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.91e-7 AC: 1AN: 1447102Hom.: 0 Cov.: 32 AF XY: 0.00000139 AC XY: 1AN XY: 718260
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 06, 2024 | Not observed in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on splicing; Identified in a patient with hypertrophic cardiomyopathy in the published literature (PMID: 36204818); This variant is associated with the following publications: (PMID: 37652022, 36204818) - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 05, 2019 | Variant summary: TNNT2 c.821+5G>A alters a conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: four predict the variant abolishes a 5' splicing donor site (ACMG PP3). However, these predictions have yet to be confirmed by functional studies. The variant was absent in 222940 control chromosomes (gnomAD) (ACMG PM2). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.821+5G>A in individuals affected with Cardiomyopathy and no experimental evidence demonstrating its impact on protein function have been reported in the literature. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as likely pathogenic while noting that it has been identified independently of additional cardiogenetic variants in several individuals referred for HCM genetic testing at their laboratory (GeneDx 2016). However, the exact number of functional meiotic transmissions is not specified, therefore, we have not considered this information to support co-segregation within the context of our evaluation at this time. This variant was initially identified in one adult (age >40) male patient referred for a Familial Cardiomyopathy evaluation at our laboratory. However, this patient is lost to follow-up and no information pertaining to clinical history and/or co-segregation with disease is available at this time. Other variants affecting the same canonical splice site (c.821+1G>A, c.821+1G>C and c.821+1G>T) have been reported in association with HCM (HGMD and in the Atlas of Cardiac Genetic Variation database) but that does not unequivocally prove causation for this variant located outside of the canonical splice site in the TNNT2 gene. Therefore, based strictly on the limited information available as outlined above, the variant was classified as VUS-possibly pathogenic. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Jan 05, 2018 | - - |
Dilated cardiomyopathy 1D;C1861864:Hypertrophic cardiomyopathy 2;C2676271:Cardiomyopathy, familial restrictive, 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | This sequence change falls in intron 15 of the TNNT2 gene. It does not directly change the encoded amino acid sequence of the TNNT2 protein. It affects a nucleotide within the consensus splice site. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 36204818). ClinVar contains an entry for this variant (Variation ID: 36886). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at